Tango Therapeutics, Inc.

Tango Therapeutics maintains a robust balance sheet with $157.8 million in cash and equivalents against $44.3 million in total liabilities, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 27.38. The company reported a net loss of $45.5 million in Q1 2026, driven by an operating loss of $48.8 million. Free cash flow was negative $44.4 million, reflecting ongoing operational expenditures. The market capitalization stands at $3.01 billion, implying a price-to-book ratio of 7.7, which is elevated relative to tangible assets given the lack of profitability.

Profitability metrics remain negative, with a return on equity of -26.0% and a return on assets of -23.3%. The company has not yet achieved revenue scale, reporting $0.0 in revenue for the latest period, which renders traditional margin analysis inapplicable. The EV/EBITDA ratio is negative -23.7, consistent with pre-commercial biotech firms investing heavily in research and development. Without cohort median data for direct comparison, the company’s financial profile aligns with typical early-stage pharmaceutical developers prioritizing pipeline advancement over near-term earnings.

Revenue concentration is currently non-existent from product sales, with historical revenue derived from collaboration and license fees. The company’s activities are focused on domestic operations, as indicated by the reporting of domestic R&D expenses. There is no disclosed geographic revenue mix for product sales, as the company is pre-commercial. The primary financial inflows from operations are tied to milestone payments and collaboration agreements rather than direct product sales.

Growth trajectory is characterized by increasing share count and capital raises rather than revenue expansion. Shares outstanding increased from 107.7 million in Q1 2025 to 144.2 million in Q1 2026, a 34% increase, driven by at-the-market offerings and stock plan issuances. The company raised $62.8 million net from at-the-market offerings in Q1 2026 alone. This capital infusion supports the continued development of its pipeline, including programs like TNG961 and TNG260, but dilutes existing shareholders.

Risk assessment indicates low liquidity risk due to the strong cash position, but medium dilution risk is flagged. Key risks include the potential need for additional capital raises, which may cause further dilution or require relinquishing rights to technologies. The company’s reliance on external funding and the binary nature of clinical trial outcomes present significant uncertainties. The absence of revenue and consistent net losses underscore the speculative nature of the investment.

Recent events include the issuance of common stock under stock plans and at-the-market offerings in Q1 2026. The company also reported stock-based compensation expense of $10.8 million in the quarter. Analyst sentiment remains positive, with a mean price target of $44.18 and a mean recommendation of 1.62 (strong buy). The high price target of $69.00 suggests significant upside potential if clinical milestones are met, while the low target of $24.00 reflects downside risk.

Analysts project 13.9% upside to a mean price target of $23.90, reflecting a consensus buy recommendation from 12 analysts.

The company maintains a strong liquidity position with a current ratio of 16.32, significantly reducing short-term solvency risks.

Operating margin of -1.78 outperforms the biotechnology cohort median of -3.81, indicating relatively better cost efficiency.

Revenue grew at a 7.3% CAGR from FY2023 to FY2025, demonstrating consistent top-line expansion over the period.

The company faces medium dilution risk, which could erode shareholder value as it seeks to fund ongoing operations.

Free cash flow deteriorated to -$139.9 million in FY2025, highlighting significant cash burn and reliance on external financing.

Return on invested capital stands at -28.4%, indicating inefficient use of capital and negative value creation for investors.

Revenue $0.00; Operating income -$48.8M.

• ▍Revenue $0.00
• ▍Operating income -$48.8M

Revenue $62.4M; Operating income -$69.4M.

• ▍Revenue $62.4M
• ▍Operating income -$69.4M
• ▍Net margin -100.7%

Revenue $8.6M; Operating income -$83.5M.

• ▍Revenue $8.6M
• ▍Operating income -$83.5M
• ▍Net margin -918.3%

Revenue $62.4M; Operating income -$111.3M.

• ▍Revenue $62.4M
• ▍Operating income -$111.3M
• ▍Net margin -162.9%

Revenue $42.1M; Operating income -$145.6M.

• ▍Revenue $42.1M
• ▍Operating income -$145.6M
• ▍Net margin -309.7%

Revenue $42.1M; Operating income -$145.6M.

• ▍Revenue $42.1M
• ▍Operating income -$145.6M
• ▍Net margin -309.7%

Revenue $36.5M; Operating income -$114.2M.

• ▍Revenue $36.5M
• ▍Operating income -$114.2M
• ▍Net margin -278.5%

Revenue $36.5M; Operating income -$114.2M.

• ▍Revenue $36.5M
• ▍Operating income -$114.2M
• ▍Net margin -278.5%